Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 10:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Ocular Coherence Tomography-Angiography (OCT-A) Clear all
Recruiting Phase 4 Interventional Accepts healthy volunteers

Retinal Blood Flow and Autoregulation

NCT05344274
View directory record Official record
Conditions
Glaucoma
Interventions
Indocyanine Green Angiography, Isocapnic Oxygen, Ocular Imaging with Optical Coherence Tomography (OCT) and Adaptive Optics (AO)
Diagnostic Test · Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
4
States / cities
Baltimore, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 1, 2026, 10:24 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Evaluation of the Repeatability and Reproducibility of OCTA Image Quality With the Heidelberg Engineering SPECTRALIS With OCT Angiography Module

NCT03530449
View directory record Official record
Conditions
Retinal Vascular, Normal Eyes
Interventions
OCT Angiography, Color Fundus Photography, Optical Coherence Tomography
Device
Lead sponsor
Heidelberg Engineering GmbH
Industry
Eligibility
22 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Oct 1, 2026, 10:24 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

OCT Angiography in Wet AMD

NCT02253030
View directory record Official record
Conditions
Neovascular (Wet) Age-related Macular Degeneration (AMD)
Interventions
Optical Coherence Tomography
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
50 Years to 100 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Oct 1, 2026, 10:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Multimodal Ocular Imaging in Neurodegeneration

NCT03699644
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Dementia, Frontotemporal Dementia
Interventions
Spectral-Domain Optical Coherence Tomography (SD-OCT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Comprehensive Ophthalmic Examination, Fundus Photography
Device · Diagnostic Test
Lead sponsor
University of Michigan
Other
Eligibility
45 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 1, 2026, 10:24 PM EDT
Not listed Not applicable Interventional

Combined Effects of Diabetes Self-Management Education and Nutritional Supplementation on Visual Function and Retinopathy

NCT04120077
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Retinopathy
Interventions
EyePromise DVS, EyePromise DVS plus EyePromise EZTears
Dietary Supplement
Lead sponsor
ZeaVision, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 1, 2026, 10:24 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

OCT Angiography and NRAI in Dementia

NCT03761381
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Mild Cognitive Impairment
Interventions
Optical Coherence Tomography Angiography (OCTA) Imaging, Noninvasive Retinal Amyloid Imaging (NRAI)
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 1, 2026, 10:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Imaging of Retinochoroidal Vasculature in Patients Being Assessed for Cardiovascular Disease

NCT05082402
View directory record Official record
Conditions
Cardiovascular Diseases, Retina; Change
Interventions
Swept Source Optical Coherence Tomography Angiography
Diagnostic Test
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 95 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 1, 2026, 10:24 PM EDT
Terminated Phase 2 Interventional Results available

Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma

NCT01471054
View directory record Official record
Conditions
Macular Edema, Cystoid Macular Edema, Uveal Melanoma, Radiation Maculopathy, Radiation Retinopathy
Interventions
Ozurdex, Bevacizumab
Drug
Lead sponsor
Arman Mashayekhi
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Oct 1, 2026, 10:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Atlas of Retinal Imaging in Alzheimer's Study

NCT03862222
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia, Aging, Cognitive Change
Interventions
Retinal Imaging, Pupillometry, Contrast Sensitivity, Neuropsychological Evaluation, APOE genotyping, blood draw, Gait Assessment, Actigraphy
Other · Diagnostic Test · Genetic
Lead sponsor
University of Rhode Island
Other
Eligibility
55 Years to 80 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
4
States / cities
Clearwater, Florida • St. Petersburg, Florida • Kingston, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 1, 2026, 10:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema

NCT01934556
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab 0.3 mg intravitreal injection, Guided Laser Photocoagulation
Drug · Device
Lead sponsor
Palmetto Retina Center, LLC
Other
Eligibility
18 Years to 100 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Beverly Hills, California • West Columbia, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 1, 2026, 10:24 PM EDT
Completed Phase 3 Interventional Results available

Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization

NCT00436553
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
Verteporfin Photodynamic Therapy, Ranibizumab, Verteporfin Placebo, Ranibizumab Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
36
States / cities
Tucson, Arizona • Beverly Hills, California • Oakland, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 1, 2026, 10:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Additional Heidelberg Engineering SPECTRALIS With OCT Angiography Module (OCTA Module) Scan Types

NCT04604002
View directory record Official record
Conditions
Retinal Vascular, Normal Eyes
Interventions
OCT Angiography, Color Fundus Photography, Optical Coherence Tomography
Device
Lead sponsor
Heidelberg Engineering GmbH
Industry
Eligibility
22 Years and older
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 1, 2026, 10:24 PM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.

NCT02222610
View directory record Official record
Conditions
Radiation Retinopathy
Interventions
0.5 mg ranibizumab, Targeted Retinal Photocoagulation (TRP)
Drug · Procedure
Lead sponsor
Greater Houston Retina Research
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
4
States / cities
Dallas, Texas • Houston, Texas • Katy, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Oct 1, 2026, 10:24 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

WF and PR OCTA in Diabetic Retinopathy

NCT03922932
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 1, 2026, 10:24 PM EDT
Recruiting No phase listed Observational

Imaging Retinal Vasculature in Infant Eyes

NCT05558059
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Handheld Optical Coherence Tomography with OCT Angiography
Device
Lead sponsor
Duke University
Other
Eligibility
Up to 2 Months
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 1, 2026, 10:24 PM EDT
Terminated Not applicable Interventional Results available

SD-OCT Angiography

NCT02510885
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Age-related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
AngioVue SD-OCT
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 1, 2026, 10:24 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Tebentafusp for Uveal Melanoma

NCT06414590
View directory record Official record
Conditions
Locally Advanced Unresectable Uveal Melanoma
Interventions
Tebentafusp-Tebn
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 1, 2026, 10:24 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Intraoperative OCT Guidance of Intraocular Surgery II

NCT03713268
View directory record Official record
Conditions
Macular Holes, Epiretinal Membrane, Diabetic Retinopathy, Retinal Detachment, Retinal Disease, Preretinal Fibrosis, Cataract, Ocular Tumor, Strabismus, Healthy
Interventions
Microscope integrated optical coherence tomography
Device
Lead sponsor
Duke University
Other
Eligibility
4 Weeks and older
Enrollment
262 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 1, 2026, 10:24 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Retinal Microanatomy in Retinopathy of Prematurity (BabySTEPS2)

NCT04995341
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Investigational ultracompact OCT and OCTA system, retinal photographs
Device
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
236 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
2
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 1, 2026, 10:24 PM EDT
Not listed No phase listed Observational

Non Exudative AMD Imaged With SS-OCT

NCT03688243
View directory record Official record
Conditions
Dry Macular Degeneration
Interventions
SS-OCT imaging
Device
Lead sponsor
Boston Image Reading Center
Industry
Eligibility
50 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 1, 2026, 10:24 PM EDT
Not listed No phase listed Observational

Non Exudative AMD Imaged With SS-OCT- Extension

NCT04469140
View directory record Official record
Conditions
Dry Macular Degeneration
Interventions
SS-OCT imaging
Device
Lead sponsor
Boston Image Reading Center
Industry
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 1, 2026, 10:24 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

OCT Biomarkers for Diabetic Retinopathy

NCT02330042
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 79 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 1, 2026, 10:24 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Caffeine Consumption in Glaucoma Patients and Healthy Subjects

NCT03675412
View directory record Official record
Conditions
Glaucoma, Primary Open Angle
Interventions
Caffeine tablet
Dietary Supplement
Lead sponsor
Wills Eye
Other
Eligibility
18 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 1, 2026, 10:24 PM EDT
Completed Phase 2 Interventional Results available

Sildenafil for Treatment of Choroidal Ischemia

NCT04356716
View directory record Official record
Conditions
Choroidal Ischemia, Vitelliform Macular Dystrophy, Age-related Macular Degeneration, Central Serous Retinopathy, Retinitis Pigmentosa
Interventions
Sildenafil, Standard of Care Sildenafil, Ocular Coherence Tomography-Angiography (OCT-A), Visual Acuity (VA)
Drug · Other · Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 1, 2026, 10:24 PM EDT